Id: acc1361
Group: 2sens
Protein: Raptor
Gene Symbol: RPTOR
Protein Id: Q8N122
Protein Name: RPTOR_HUMAN
PTM: phosphorylation
Site: Ser792
Site Sequence: TIDKMRRASSYSSLNSLIGVS
Disease Category: Cancer
Disease: Prostate Cancer
Disease Subtype: CRPC
Disease Cellline: C4-2
Disease Info:
Drug: salinomycin
Drug Info: "Salinomycin is a polyether ionophore antibiotic primarily used as an anticoccidial agent in poultry and as a growth promoter in livestock, with emerging research interest in its potential anticancer properties. "
Effect: modulate
Effect Info: "Salinomycin inhibits the phosphorylation of AR and promotes the phosphorylation of AMPK. The activation of AMPK leads to an increase in the phosphorylation of Raptor and TSC2 at Ser1387. Meanwhile, salinomycin also blocks the inhibitory phosphorylation of TSC2 (Ser939/Thr1462) by AKT, thereby inhibiting AR and mTORC1 through a dual - effect mechanism."
Note:
Score: 4.0
Pubmed(PMID): 27557496
Sentence Index:
Sentence:

Sequence & Structure:

MESEMLQSPLLGLGEEDEADLTDWNLPLAFMKKRHCEKIEGSKSLAQSWRMKDRMKTVSVALVLCLNVGVDPPDVVKTTPCARLECWIDPLSMGPQKALETIGANLQKQYENWQPRARYKQSLDPTVDEVKKLCTSLRRNAKEERVLFHYNGHGVPRPTVNGEVWVFNKNYTQYIPLSIYDLQTWMGSPSIFVYDCSNAGLIVKSFKQFALQREQELEVAAINPNHPLAQMPLPPSMKNCIQLAACEATELLPMIPDLPADLFTSCLTTPIKIALRWFCMQKCVSLVPGVTLDLIEKIPGRLNDRRTPLGELNWIFTAITDTIAWNVLPRDLFQKLFRQDLLVASLFRNFLLAERIMRSYNCTPVSSPRLPPTYMHAMWQAWDLAVDICLSQLPTIIEEGTAFRHSPFFAEQLTAFQVWLTMGVENRNPPEQLPIVLQVLLSQVHRLRALDLLGRFLDLGPWAVSLALSVGIFPYVLKLLQSSARELRPLLVFIWAKILAVDSSCQADLVKDNGHKYFLSVLADPYMPAEHRTMTAFILAVIVNSYHTGQEACLQGNLIAICLEQLNDPHPLLRQWVAICLGRIWQNFDSARWCGVRDSAHEKLYSLLSDPIPEVRCAAVFALGTFVGNSAERTDHSTTIDHNVAMMLAQLVSDGSPMVRKELVVALSHLVVQYESNFCTVALQFIEEEKNYALPSPATTEGGSLTPVRDSPCTPRLRSVSSYGNIRAVATARSLNKSLQNLSLTEESGGAVAFSPGNLSTSSSASSTLGSPENEEHILSFETIDKMRRASSYSSLNSLIGVSFNSVYTQIWRVLLHLAADPYPEVSDVAMKVLNSIAYKATVNARPQRVLDTSSLTQSAPASPTNKGVHIHQAGGSPPASSTSSSSLTNDVAKQPVSRDLPSGRPGTTGPAGAQYTPHSHQFPRTRKMFDKGPEQTADDADDAAGHKSFISATVQTGFCDWSARYFAQPVMKIPEEHDLESQIRKEREWRFLRNSRVRRQAQQVIQKGITRLDDQIFLNRNPGVPSVVKFHPFTPCIAVADKDSICFWDWEKGEKLDYFHNGNPRYTRVTAMEYLNGQDCSLLLTATDDGAIRVWKNFADLEKNPEMVTAWQGLSDMLPTTRGAGMVVDWEQETGLLMSSGDVRIVRIWDTDREMKVQDIPTGADSCVTSLSCDSHRSLIVAGLGDGSIRVYDRRMALSECRVMTYREHTAWVVKASLQKRPDGHIVSVSVNGDVRIFDPRMPESVNVLQIVKGLTALDIHPQADLIACGSVNQFTAIYNSSGELINNIKYYDGFMGQRVGAISCLAFHPHWPHLAVGSNDYYISVYSVEKRVR

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

Target Drug name MOA Phase Status Disease Source
RPTOR INDOXIMOD mTORC1 activator 2 Completed metastatic prostate cancer ClinicalTrials
RPTOR INDOXIMOD mTORC1 activator 2 Terminated melanoma ClinicalTrials
RPTOR INDOXIMOD mTORC1 activator 2 Completed breast cancer ClinicalTrials
RPTOR INDOXIMOD mTORC1 activator 1 Completed acute myeloid leukemia ClinicalTrials
RPTOR INDOXIMOD mTORC1 activator 1 Completed glioblastoma multiforme ClinicalTrials
RPTOR INDOXIMOD mTORC1 activator 1 Withdrawn neoplasm ClinicalTrials
RPTOR INDOXIMOD mTORC1 activator 1 Completed metastatic melanoma ClinicalTrials
RPTOR INDOXIMOD mTORC1 activator 1 Completed pancreatic carcinoma ClinicalTrials
RPTOR INDOXIMOD mTORC1 activator 1 Completed medulloblastoma ClinicalTrials
RPTOR INDOXIMOD mTORC1 activator 1 Terminated non-small cell lung carcinoma ClinicalTrials
RPTOR INDOXIMOD mTORC1 activator 1 Completed ependymoma ClinicalTrials
RPTOR INDOXIMOD mTORC1 activator 1 Completed pancreatic adenocarcinoma ClinicalTrials
RPTOR INDOXIMOD mTORC1 activator 1 Completed Paraganglioma ClinicalTrials
ClinicalTrials
RPTOR INDOXIMOD mTORC1 activator 1 Completed gliosarcoma ClinicalTrials
ClinicalTrials
RPTOR INDOXIMOD mTORC1 activator 1 Completed brain cancer ClinicalTrials

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC

No intensity data of this site,
show all other sites!

RPTOR-Ser538
Cancer Intensity
BRCA
COAD
HGSC -2.105
ccRCC 0.199
GBM -0.127
HNSC 1.471
LUAD 0.179
LUSC 0.328
non_ccRCC
PDAC -0.294
UCEC 0.349
RPTOR-Ser546
Cancer Intensity
BRCA
COAD
HGSC -1.002
ccRCC 0.116
GBM 0.758
HNSC 1.261
LUAD -1.333
LUSC
non_ccRCC
PDAC
UCEC 0.201
RPTOR-Ser561
Cancer Intensity
BRCA 0.611
COAD 1.039
HGSC 2.041
ccRCC -1.116
GBM 0.372
HNSC -0.804
LUAD -0.716
LUSC 0.15
non_ccRCC 0.268
PDAC -1.07
UCEC -0.774
RPTOR-Ser563
Cancer Intensity
BRCA
COAD
HGSC 1.094
ccRCC
GBM
HNSC
LUAD -0.227
LUSC -0.867
non_ccRCC
PDAC
UCEC
RPTOR-Ser564
Cancer Intensity
BRCA
COAD -1.082
HGSC 0.89
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC 0.192
PDAC
UCEC
RPTOR-Ser701
Cancer Intensity
BRCA -1.62
COAD 0.741
HGSC -1.71
ccRCC -0.602
GBM 0.636
HNSC 1.239
LUAD 0.522
LUSC -0.209
non_ccRCC 1.07
PDAC 0.229
UCEC -0.296
RPTOR-Ser705
Cancer Intensity
BRCA 1.313
COAD 0.847
HGSC -0.085
ccRCC -0.686
GBM -0.814
HNSC 0.98
LUAD -1.463
LUSC 1.334
non_ccRCC 0.141
PDAC -0.401
UCEC -1.165
RPTOR-Ser719
Cancer Intensity
BRCA -1.177
COAD -0.534
HGSC 1.727
ccRCC 0.003
GBM 0.631
HNSC -0.167
LUAD -0.06
LUSC 1.458
non_ccRCC -1.489
PDAC -0.695
UCEC 0.304
RPTOR-Ser723
Cancer Intensity
BRCA
COAD 0.037
HGSC
ccRCC
GBM 0.447
HNSC -1.4
LUAD
LUSC
non_ccRCC
PDAC
UCEC 0.916
RPTOR-Ser724
Cancer Intensity
BRCA
COAD -0.707
HGSC
ccRCC
GBM 0.707
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC
RPTOR-Ser726
Cancer Intensity
BRCA
COAD 0.288
HGSC
ccRCC -0.985
GBM 1.396
HNSC
LUAD -0.964
LUSC
non_ccRCC
PDAC
UCEC 0.264
RPTOR-Ser727
Cancer Intensity
BRCA
COAD 0.131
HGSC
ccRCC 1.489
GBM -0.574
HNSC
LUAD 0.143
LUSC
non_ccRCC
PDAC
UCEC -1.19
RPTOR-Ser729
Cancer Intensity
BRCA
COAD 1.067
HGSC
ccRCC 1.493
GBM -1.426
HNSC -0.694
LUAD -0.226
LUSC 0.039
non_ccRCC
PDAC
UCEC -0.253
RPTOR-Thr541
Cancer Intensity
BRCA
COAD
HGSC
ccRCC -0.558
GBM
HNSC
LUAD -0.596
LUSC
non_ccRCC
PDAC
UCEC 1.154
RPTOR-Thr542
Cancer Intensity
BRCA
COAD
HGSC -0.443
ccRCC
GBM
HNSC
LUAD -0.702
LUSC
non_ccRCC
PDAC
UCEC 1.145
RPTOR-Thr548
Cancer Intensity
BRCA -0.574
COAD
HGSC 0.94
ccRCC -0.645
GBM 0.28
HNSC 0.05
LUAD -1.178
LUSC 2.253
non_ccRCC -0.633
PDAC -0.639
UCEC 0.146
RPTOR-Thr556
Cancer Intensity
BRCA
COAD
HGSC -0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC 0.707
RPTOR-Thr699
Cancer Intensity
BRCA
COAD
HGSC
ccRCC -0.559
GBM
HNSC 1.155
LUAD -0.595
LUSC
non_ccRCC
PDAC
UCEC
RPTOR-Thr725
Cancer Intensity
BRCA
COAD -0.07
HGSC 0.448
ccRCC -0.985
GBM 1.266
HNSC -0.906
LUAD -0.965
LUSC
non_ccRCC
PDAC
UCEC 1.212
RPTOR-Tyr534
Cancer Intensity
BRCA
COAD
HGSC
ccRCC -0.927
GBM
HNSC
LUAD -0.132
LUSC
non_ccRCC
PDAC
UCEC 1.059

PTM-Disease Association:

source: PTMD

No data.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: